Back to News
Market Impact: 0.35
CC Shareholder Alert: December 7, 2026 Lead Plaintiff Deadline in The Chemours Company Securities Class Action
Source: globenewswire.com
Analyst InsightsCorporate Guidance & OutlookLegal & LitigationCompany Fundamentals
UBS, Morgan Stanley and J.P. Morgan cut Chemours price targets by as much as 37.9% after the company reduced its 2026 guidance. A lawsuit alleges the guidance cut followed months of overstated Opteon aftermarket demand; the claim is an allegation, not an established finding.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
CC-0.85
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash